US · QDEL · MEDICAL - INSTRUMENTS & SUPPLIES
QuidelOrtho Corporation (QDEL) intrinsic value and stock valuation
$8.32as of 2026-11-21 · Mkt cap 837.73M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
QuidelOrtho Corporation DCF and intrinsic value
InvestorsCraft values QDEL with the Chepakovich two-stage DCF model — currently rated undervalued. How the model works · Run your own DCF prefilled from QDEL’s statements →
QuidelOrtho Corporation Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2010–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Revenue | $2.73B | $2.78B | $3B | $1.7B | $1.66B |
| Operating income | -$-919.2M | -$-1.96B | $139.1M | $906M | $1.06B |
| Net income | -$-1.13B | -$-2.05B | -$-10.1M | $704.2M | $810.3M |
| EPSd | -$-16.69M | -$-30.54M | -$-151.2K | $16.4M | $18.6M |
| Operating cash flow | $105.2M | $83M | $280.2M | $805.9M | $629.8M |
| Capital expenditure | -$-188.2M | -$-195.1M | -$-209.3M | -$-292.72M | -$-64.93M |
| Free cash flow | -$-83M | -$-112.1M | $70.9M | $513.1M | $564.8M |
| Total assets | $5.77B | $6.42B | $8.56B | $2.43B | $1.87B |
| Total debt | $2.83B | $2.68B | $2.61B | $139.3M | $108.5M |
| Net debt | $2.66B | $2.58B | $2.5B | -$-663.5M | -$-381.44M |
| Total equity | $1.92B | $2.98B | $5.01B | $1.93B | $1.33B |
| Cash and short-term investments | $202.2M | $98.3M | $167.3M | $828.5M | $489.9M |
Income statement
| 2025 | 2024 | 2023 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Revenue | $2.73B | $2.78B | $3B | $1.7B | $1.66B |
| Cost of revenue | $1.46B | $1.5B | $1.5B | $420.3M | $312.8M |
| Gross profit | $1.27B | $1.29B | $1.5B | $1.28B | $1.35B |
| Research and development expenses | $186.2M | $218.7M | $246.8M | $95.7M | $84.3M |
| Selling, general and administrative expenses | $746.3M | $766.8M | $763.2M | $239.6M | $200.5M |
| Other expenses | $1.26B | $2.26B | $349.8M | $37M | $3.69M |
| Operating expenses | $2.19B | $3.25B | $1.36B | $372.3M | $288.5M |
| Cost and expenses | $3.65B | $4.74B | $2.86B | $792.6M | $601.3M |
| Interest income | $0.00 | $0.00 | $2.2M | $300K | $0.00 |
| Interest expense | $177.6M | $188.3M | $178.9M | $700K | $1.26M |
| Depreciation and amortization | $442M | $453.4M | $457.2M | $52.7M | $49.1M |
| Ebitda | -$-488.1M | -$-1.49B | $607M | $953.3M | $1.1B |
| Operating income | -$-919.2M | -$-1.96B | $139.1M | $906M | $1.06B |
| Total other income/expenses, net | -$-188.5M | -$-170.6M | -$-168.2M | -$-5.7M | -$-20.01M |
| Income before tax | -$-1.11B | -$-2.13B | -$-29.1M | $900.3M | $1.04B |
| Income tax expense | $24.1M | -$-79.5M | -$-19M | $196.1M | $230M |
| Net income | -$-1.13B | -$-2.05B | -$-10.1M | $704.2M | $810.3M |
| Weighted average shares outstanding | $67.8M | $67.2M | $66.8M | $42.1M | $42.1M |
| Weighted average diluted shares outstanding | $67.8M | $67.2M | $66.8M | $42.9M | $43.6M |
Balance sheet
| 2025 | 2024 | 2023 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $202.2M | $98.3M | $167.3M | $828.5M | $489.9M |
| Net receivables | $417M | $451.3M | $488.4M | $393.8M | $529.2M |
| Inventory | $577.6M | $533.7M | $577.8M | $198.8M | $113.8M |
| Total current assets | $1.45B | $1.22B | $1.31B | $1.44B | $1.14B |
| Property, plant and equipment, net | $1.51B | $1.55B | $1.61B | $476.8M | $211M |
| Goodwill and intangible assets | $2.56B | $3.39B | $5.43B | $435.7M | $459.5M |
| Long-term investments | $0.00 | $21.7M | $7.4M | $37.9M | $0.00 |
| Total non-current assets | $4.32B | $5.2B | $7.25B | $990.1M | $728.8M |
| Total assets | $5.77B | $6.42B | $8.56B | $2.43B | $1.87B |
| Accounts payable | $279.4M | $246M | $294.8M | $101.5M | $86.3M |
| Short-term debt | $207.6M | $372.9M | $166.5M | $10.3M | $7.8M |
| Deferred revenue | $37.8M | $33.5M | $36.8M | $1.9M | $3.73M |
| Total current liabilities | $966.1M | $998.8M | $833.8M | $323.5M | $337M |
| Long-term debt | $2.63B | $2.31B | $2.45B | $129M | $100.7M |
| Deferred revenue, non-current | $0.00 | $17.3M | $0.00 | $0.00 | -$-38.33M |
| Total non-current liabilities | $2.88B | $2.44B | $2.72B | $177.5M | $201.5M |
| Capital lease obligations | $183.7M | $198.3M | $199.5M | $138.6M | $108.5M |
| Total liabilities | $3.85B | $3.44B | $3.56B | $501M | $538.5M |
| Common stock | $100K | $100K | $100K | $0.00 | $40K |
| Retained earnings | -$-996M | $135.8M | $2.19B | $1.65B | $945M |
| Accumulated other comprehensive income (loss) | -$-15.4M | -$-36.2M | -$-30M | $400K | -$-430K |
| Total equity | $1.92B | $2.98B | $5.01B | $1.93B | $1.33B |
| Total investments | $32.4M | $21.7M | $55.8M | $63.6M | $0.00 |
| Total debt | $2.83B | $2.68B | $2.61B | $139.3M | $108.5M |
| Net debt | $2.66B | $2.58B | $2.5B | -$-663.5M | -$-381.44M |
Cash flow statement
| 2025 | 2024 | 2023 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Net income | -$-1.13B | -$-2.05B | -$-10.1M | $704.2M | $810.3M |
| Depreciation and amortization | $442M | $453.4M | $457.2M | $54.4M | $49.1M |
| Stock-based compensation | $45.9M | $42.1M | $51.6M | $25.4M | $21M |
| Change in working capital | -$-125.8M | -$-158.7M | -$-194.9M | -$-2.78M | -$-251.07M |
| Accounts receivable | -$-117.5M | $5.4M | $160M | $118.9M | -$-402.09M |
| Inventory | -$-148.3M | -$-134.1M | -$-211.6M | -$-85.04M | -$-54.9M |
| Accounts payable | $40M | -$-23.4M | $3M | $10.5M | $52.2M |
| Net cash provided by operating activities | $105.2M | $83M | $280.2M | $805.9M | $629.8M |
| Investments in property, plant and equipment | -$-188.2M | -$-195.1M | -$-209.3M | -$-292.72M | -$-64.93M |
| Acquisitions, net | $6.5M | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-192.7M | -$-149.9M | -$-187.6M | -$-319.53M | -$-63.32M |
| Common stock issued | $6.1M | $5M | $11.6M | $7.6M | $9.61M |
| Common stock repurchased | $0.00 | $0.00 | -$-7.2M | -$-103.44M | -$-43.69M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $155.8M | $48.8M | -$-265.8M | -$-173.18M | -$-130.28M |
| Net change in cash | $71.3M | -$-21M | -$-174.4M | $312.8M | $437.2M |
| Cash at end of period | $169.8M | $98.5M | $119.5M | $802.8M | $489.9M |
| Operating cash flow | $105.2M | $83M | $280.2M | $805.9M | $629.8M |
| Capital expenditure | -$-188.2M | -$-195.1M | -$-209.3M | -$-292.72M | -$-64.93M |
| Free cash flow | -$-83M | -$-112.1M | $70.9M | $513.1M | $564.8M |
Line items
Line items
Line items
About QuidelOrtho Corporation
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
- CEO
- Brian J. Blaser
- Employees
- 6.5K
- Beta
- 0.69
Explore
Frequently asked questions
What is the intrinsic value of QuidelOrtho Corporation (QDEL)?
QuidelOrtho Corporation (QDEL) is currently undervalued based on the InvestorsCraft IC model — IC value is 20–50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is QDEL undervalued?
QDEL trades at a price of $8.32 (Nov 21, 2026): undervalued — IC value is 20–50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.